This presentation will discuss the evolution of the end-stage renal disease (ESRD) bundle, the intent of the Transitional Drug Add-On Payment Adjustment (TDAPA), the valuation and inclusion of calcimimetics as part of the bundle for 2021, and reimbursement beyond the bundle.
Sponsored by